Modulation Expression of Tumor Necrosis Factor α in the Radiation-induced Lung Injury by Glycyrrhizic Acid
Overview
Affiliations
To evaluate the ability of glycyrrhizic acid (GLA) to reduce the tumor necrosis factor α (TNF-α), release on messenger ribonucleic acid (mRNA) and protein production in the lungs using GLA in response to irradiation were studied. The animals were divided into four groups: No treatment (NT group), GLA treatment only (GLA group), irradiation only (XRT group), and GLA treatment plus irradiation (GLA/XRT group). Rats were killed at different time points. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) was used to evaluate the mRNA expression of TNF-α in the lungs (compared with non-irradiated lungs). An enzyme-linked immunosorbant assay (ELISA) assay was used to measure the TNF-α protein level. The TNF-α mRNA expression in the lungs of the XRT rats was clearly higher at all-time points compared to the NT rats. The TNF-α mRNA expression in the lungs of the GLA/XRT rats was lower at all-time points compared to the XRT rats. Release of the TNF-α on protein level in the lungs of the XRT rats increased at all-time points compared to the NT rats. In contrast to the XRT rats, the lungs of the GLA/XRT rats revealed a reduction on TNF-α protein level at 6 h after irradiation. This study has clearly showed the immediate down-regulation of the TNF-α mRNA and protein production in the lungs using GLA in response to irradiation.
Promising Biomarkers of Radiation-Induced Lung Injury: A Review.
Liu X, Shao C, Fu J Biomedicines. 2021; 9(9).
PMID: 34572367 PMC: 8470495. DOI: 10.3390/biomedicines9091181.
Markers Useful in Monitoring Radiation-Induced Lung Injury in Lung Cancer Patients: A Review.
Sliwinska-Mosson M, Wadowska K, Trembecki L, Bil-Lula I J Pers Med. 2020; 10(3).
PMID: 32722546 PMC: 7565537. DOI: 10.3390/jpm10030072.
Wang S, Li L, Shi L Mol Med Rep. 2019; 20(3):2657-2666.
PMID: 31322195 PMC: 6691250. DOI: 10.3892/mmr.2019.10494.
Wei J, Xu H, Liu Y, Li B, Zhou F Oncotarget. 2017; 8(13):20842-20850.
PMID: 28209920 PMC: 5400550. DOI: 10.18632/oncotarget.15356.